CORAL GABLES, Fla., March 29, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that researchers at the University of Pennsylvania have commenced a 60 subject, double-blind, placebo-controlled, investigator-sponsored study to evaluate the use of CPP-109 (vigabatrin) for the treatment of patients addicted to both cocaine and alcohol.
